Could a diabetes drug turn back the biological clock in HIV?

NCT ID NCT07707778

First seen Jul 16, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study investigates whether tirzepatide, a drug used for diabetes and weight loss, can reverse biological aging in people with HIV who are virally suppressed and have obesity. Participants receive tirzepatide for 25 weeks after a diet program. Researchers measure epigenetic aging using DNA methylation clocks and also track changes in body fat and liver health. The goal is to see if the drug can restore a more youthful biological age and improve metabolism.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a drug called tirzepatide, which is a GLP-1 and GIP receptor agonist used for diabetes and weight loss
What this could lead to
If successful, this could show that tirzepatide slows or reverses biological aging in people with HIV, potentially reducing age-related health risks.
What could go wrong
This is a small pilot study with only 60 participants, so results may not apply to everyone. The effect on aging is measured by blood markers, not direct health outcomes, and the drug may cause side effects like nausea or digestive issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Taiwan University Hospial

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.